vs
Nextpower Inc.（NXT）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Nextpower Inc.の直近四半期売上が大きい（$909.4M vs $772.1M、Revvityの約1.2倍）。Nextpower Inc.の純利益率が高く（14.4% vs 12.7%、差は1.7%）。Nextpower Inc.の前年同期比売上増加率が高い（33.9% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $118.5M）。過去8四半期でNextpower Inc.の売上複合成長率が高い（11.1% vs 9.0%）
Nextpower Inc（証券コード：NXT）は米国カリフォルニア州フリーモントに本社を置くグローバルなエネルギーテクノロジー企業です。世界中の顧客に最先端のエネルギー技術ソリューションと関連サービスを提供し、同分野で高い技術力と市場競争力を有しています。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
NXT vs RVTY — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $909.4M | $772.1M |
| 純利益 | $131.2M | $98.4M |
| 粗利率 | 31.7% | — |
| 営業利益率 | 19.4% | 14.5% |
| 純利益率 | 14.4% | 12.7% |
| 売上前年比 | 33.9% | 5.9% |
| 純利益前年比 | 13.8% | 3.9% |
| EPS（希薄化後） | $0.85 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $909.4M | $772.1M | ||
| Q3 25 | $905.3M | $698.9M | ||
| Q2 25 | $864.3M | $720.3M | ||
| Q1 25 | $924.3M | $664.8M | ||
| Q4 24 | $679.4M | $729.4M | ||
| Q3 24 | $635.6M | $684.0M | ||
| Q2 24 | $719.9M | $691.7M | ||
| Q1 24 | $736.5M | $649.9M |
| Q4 25 | $131.2M | $98.4M | ||
| Q3 25 | $146.9M | $46.7M | ||
| Q2 25 | $157.2M | $53.9M | ||
| Q1 25 | $156.8M | $42.2M | ||
| Q4 24 | $115.3M | $94.6M | ||
| Q3 24 | $115.4M | $94.4M | ||
| Q2 24 | $121.7M | $55.4M | ||
| Q1 24 | $205.2M | $26.0M |
| Q4 25 | 31.7% | — | ||
| Q3 25 | 32.4% | 53.6% | ||
| Q2 25 | 32.6% | 54.5% | ||
| Q1 25 | 33.1% | 56.5% | ||
| Q4 24 | 35.5% | — | ||
| Q3 24 | 35.4% | 56.3% | ||
| Q2 24 | 33.0% | 55.7% | ||
| Q1 24 | 46.2% | 54.6% |
| Q4 25 | 19.4% | 14.5% | ||
| Q3 25 | 20.0% | 11.7% | ||
| Q2 25 | 21.5% | 12.6% | ||
| Q1 25 | 21.1% | 10.9% | ||
| Q4 24 | 22.1% | 16.3% | ||
| Q3 24 | 21.0% | 14.3% | ||
| Q2 24 | 22.2% | 12.4% | ||
| Q1 24 | 36.8% | 6.8% |
| Q4 25 | 14.4% | 12.7% | ||
| Q3 25 | 16.2% | 6.7% | ||
| Q2 25 | 18.2% | 7.5% | ||
| Q1 25 | 17.0% | 6.4% | ||
| Q4 24 | 17.0% | 13.0% | ||
| Q3 24 | 18.2% | 13.8% | ||
| Q2 24 | 16.9% | 8.0% | ||
| Q1 24 | 27.9% | 4.0% |
| Q4 25 | $0.85 | $0.86 | ||
| Q3 25 | $0.97 | $0.40 | ||
| Q2 25 | $1.04 | $0.46 | ||
| Q1 25 | $1.05 | $0.35 | ||
| Q4 24 | $0.79 | $0.77 | ||
| Q3 24 | $0.79 | $0.77 | ||
| Q2 24 | $0.84 | $0.45 | ||
| Q1 24 | $1.52 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $952.6M | $919.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $2.2B | $7.3B |
| 総資産 | $3.8B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $952.6M | $919.9M | ||
| Q3 25 | $845.3M | $931.4M | ||
| Q2 25 | $743.4M | $991.8M | ||
| Q1 25 | $766.1M | $1.1B | ||
| Q4 24 | $693.5M | $1.2B | ||
| Q3 24 | $561.9M | $1.2B | ||
| Q2 24 | $471.9M | $2.0B | ||
| Q1 24 | $474.1M | $1.7B |
| Q4 25 | $2.2B | $7.3B | ||
| Q3 25 | $2.0B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $961.0M | $7.8B |
| Q4 25 | $3.8B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.4B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.0B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $123.3M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $118.5M | $161.8M |
| FCFマージンFCF / 売上 | 13.0% | 21.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | 0.94× | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $587.3M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $123.3M | $182.0M | ||
| Q3 25 | $186.9M | $138.5M | ||
| Q2 25 | $81.3M | $134.3M | ||
| Q1 25 | $237.3M | $128.2M | ||
| Q4 24 | $143.8M | $174.2M | ||
| Q3 24 | $153.8M | $147.9M | ||
| Q2 24 | $120.8M | $158.6M | ||
| Q1 24 | $111.5M | $147.6M |
| Q4 25 | $118.5M | $161.8M | ||
| Q3 25 | $171.4M | $120.0M | ||
| Q2 25 | $70.1M | $115.5M | ||
| Q1 25 | $227.2M | $112.2M | ||
| Q4 24 | $134.9M | $149.8M | ||
| Q3 24 | $141.8M | $125.6M | ||
| Q2 24 | $118.0M | $136.6M | ||
| Q1 24 | $109.2M | $129.7M |
| Q4 25 | 13.0% | 21.0% | ||
| Q3 25 | 18.9% | 17.2% | ||
| Q2 25 | 8.1% | 16.0% | ||
| Q1 25 | 24.6% | 16.9% | ||
| Q4 24 | 19.9% | 20.5% | ||
| Q3 24 | 22.3% | 18.4% | ||
| Q2 24 | 16.4% | 19.7% | ||
| Q1 24 | 14.8% | 20.0% |
| Q4 25 | 0.5% | 2.6% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 1.9% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
| Q4 25 | 0.94× | 1.85× | ||
| Q3 25 | 1.27× | 2.97× | ||
| Q2 25 | 0.52× | 2.49× | ||
| Q1 25 | 1.51× | 3.03× | ||
| Q4 24 | 1.25× | 1.84× | ||
| Q3 24 | 1.33× | 1.57× | ||
| Q2 24 | 0.99× | 2.87× | ||
| Q1 24 | 0.54× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NXT
| Transferred Over Time | $763.9M | 84% |
| Transferred At Point In Time | $145.4M | 16% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
